Yarbrough Capital LLC acquired a new position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 88,163 shares of the company's stock, valued at approximately $277,000. Yarbrough Capital LLC owned approximately 0.13% of Cardiff Oncology at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in CRDF. Orbimed Advisors LLC bought a new stake in Cardiff Oncology in the fourth quarter worth approximately $6,677,000. Acorn Capital Advisors LLC acquired a new stake in Cardiff Oncology in the fourth quarter worth $6,260,000. Adage Capital Partners GP L.L.C. acquired a new stake in Cardiff Oncology in the fourth quarter worth $5,609,000. Laurion Capital Management LP acquired a new stake in Cardiff Oncology in the fourth quarter worth $2,504,000. Finally, Point72 Asset Management L.P. acquired a new stake in Cardiff Oncology in the fourth quarter worth $2,207,000. 16.29% of the stock is currently owned by institutional investors.
Cardiff Oncology Stock Performance
Shares of Cardiff Oncology stock traded down $0.43 during mid-day trading on Wednesday, hitting $3.87. 1,557,084 shares of the stock were exchanged, compared to its average volume of 1,162,637. Cardiff Oncology, Inc. has a 12 month low of $2.01 and a 12 month high of $5.64. The company has a 50-day simple moving average of $2.94 and a 200 day simple moving average of $3.49. The company has a market capitalization of $257.46 million, a P/E ratio of -4.12 and a beta of 1.61.
Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Cardiff Oncology had a negative return on equity of 73.97% and a negative net margin of 6,238.17%. The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.09 million. Analysts predict that Cardiff Oncology, Inc. will post -0.99 EPS for the current year.
Analyst Upgrades and Downgrades
Separately, HC Wainwright boosted their price objective on Cardiff Oncology from $17.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, May 9th.
Check Out Our Latest Stock Analysis on CRDF
Cardiff Oncology Company Profile
(
Free Report)
Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
Recommended Stories
Before you consider Cardiff Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiff Oncology wasn't on the list.
While Cardiff Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
